MedTrace Logo

TLN-372 in Advanced KRAS Mutant Solid Tumors

NCT07204340 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-21

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Conditions

  • KRAS Mutant Solid Tumors

Interventions

DRUG

TLN-372

Specified dose on specified days

DRUG

TLN-372 in combination with cetuximab

Specified dose on specified days

DRUG

TLN-372 in combination with pembrolizumab

Specified dose on specified days

Sponsors & Collaborators

  • Treeline Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-29
Primary Completion
2031-12-03
Completion
2032-04-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204340 on ClinicalTrials.gov